Acute renal failure caused by imiquimod 5% cream in a renal transplant patient: Review of the literature on side effects of imiquimod

Dermatology

Volumn 222, Issue 2, 2011, Pages 109-112

  Santos Juanes, J ^a   Esteve, A ^a   Mas Vidal, A ^a   Coto Segura, P ^a   Salgueiro, E ^b   Gomez E ^a   Galache Osuna, C ^c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Facultad de Medicina   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Acute renal failure; Imiquimod cream; Renal transplantation

Indexed keywords

AMOXICILLIN; CREATININE; HEMOGLOBIN; IMIQUIMOD; PARACETAMOL; STEROID; UREA;

ACUTE KIDNEY FAILURE; ACUTE VASCULAR REJECTION; ANURIA; ASTHENIA; BACKACHE; CASE REPORT; DIZZINESS; DRUG INDUCED DISEASE; FEVER; HEMODIALYSIS; HUMAN; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE NECROSIS; MALAISE; PAIN; PRIORITY JOURNAL; REVIEW; VERRUCA VULGARIS;

ACUTE KIDNEY INJURY; ADULT; AMINOQUINOLINES; CREATININE; HUMANS; INTERFERON INDUCERS; KIDNEY TRANSPLANTATION; MALE; RENAL DIALYSIS; TREATMENT OUTCOME; WARTS;

EID: 79955680863     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323737     Document Type: Review

References (60)

1. Stocfleth E, Meyer T, Benninghoff B: Successful treatment of actinic keratoses with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144: 1050-1053.
2. Ulrich C, Busch T, Meyer T, Nindl I, Schmook T, Sterry W, Stockfleth E: Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006; 155: 451-454. (Pubitemid 44050583)
3. Ben Mbareck L, Mebazaa A, Euvrard S, Frances C, Thervet E, Morel P, et al: 5% topical imiquimod tolerance in transplant recipients. Dermatology 2007; 215: 130-133. (Pubitemid 47230721)
4. Sauder DN: Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43:S6-S11. (Pubitemid 30447906)
5. Ito T, Amawaka R, Kaisho T, et al: Interferon- alpha and interleukin-12 are induced differentially by toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195: 1507-1512. (Pubitemid 34602828)
6. Kovach BT, Stasko T: Use of immunomodulators in organ transplant recipients. Dermatol Ther 2005; 18: 19-27. (Pubitemid 40685544)
7. Gupta AK, Cherman AM, Tyring SK: Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg 2004; 8: 338-352. (Pubitemid 41542423)
8. Marks R, Gebauer K, Shumack S, et al: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-813. (Pubitemid 32391169)
9. Geisse J, Caro I, Lindholm J, et al: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-733. (Pubitemid 38580549)
10. Jacobs AA, Snavely N, Markus J, Rosen T: Vasodilatory adverse events associated with topical imiquimod 5 percent cream. Dermatol Online J 2008; 15: 4.
11. Barton JC: Angioedema associated with imiquimod. J Am Acad Dermatol 2004; 51: 477.
12. Cavicchini S, Vezzoli P, Muratori S, Gianotti R: Morbilliform exanthem induced by imiquimod in a patient with drug-related immunosuppression. Clin Exp Dermatol 2009; 34: 526-527.
13. Fanti PA, Dika E, Vacari S, et al: Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol 2006; 45: 1464-1465. (Pubitemid 44869771)
14. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, Nestle F, Dummer R: Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140: 1490-1495. (Pubitemid 39627441)
15. Rajan N, Langtry JA: Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 2006; 31: 140-141.
16. Wu JK, Siller G, Strutton G: Psoriasis induced by topical imiquimod. Australas J Dermatol 2004; 45: 47-50. (Pubitemid 38315850)
17. Yang FC, Jessup C, Dahiya M, Reynolds R: Pityriasis rubra pilaris exacerbation with topical use of imiquimod. Int J Dermatol 2008; 47: 1076-1078.
18. Pini AM, Koch S, Schärer L, French LE, Läuchli S, Hofbauer GF: Eruptive keratoacanthoma following topical imiquimod for in situ squamous cell carcinoma of the skin in a renal transplant recipient. J Am Acad Dermatol 2008; 59:s116-117.
19. D'Addario S, Carrington PR: Multiple keratoacanthomas as an untoward response to imiquimod therapy for actinic keratoses. Acta Derm Venereol 2006; 86: 366-367. (Pubitemid 44133392)
20. Singh S, Bunker CB: Squamous cell carcinoma on the scalp following treatment with 5% imiquimod cream. Clin Exp Dermatol 2007; 32: 594-595. (Pubitemid 47231155)
21. Fernández-Vozmediano J, Armario-Hita J: Infiltrative squamous cell carcinoma on the scalp after treatment with 5% imiquimod cream. J Am Acad Dermatol 2005; 52: 716-717. (Pubitemid 40585459)
22. Marty CL, Randle HW, Walsh JS: Eruptive epidermoid cysts resulting from treatment with imiquimod. Dermatol Surg 2005; 31: 780-782, discussion 782-783.
23. Nasca MR, De Pasquale R, Micali G: Multiple and clustered eruptive epidermoid cysts following treatment with topical imiquimod. Dermatology 2007; 215: 352-353. (Pubitemid 47519266)
24. Stinco G, Frattasio A, Forcione M, Quinkenstein E, Finato N, Patrone P: The appearance of inflammatory papules in the skin surrounding areas treated with imiquimod cream for basal cell carcinoma. Br J Dermatol 2008; 158: 408-409.
25. Treviño J, Prieto VG, Hearne R, Polk A, Diwan AH: Atypical lymphocytic reaction with epidermotropism and lymphocytic vasculopathic reaction (lymphocytic vasculitis) after treatment with imiquimod. J Am Acad Dermatol 2006; 55:S123-125. (Pubitemid 44556879)
26. Burnett TJ, English JC 3rd, Ferris LK: Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses. J Drugs Dermatol 2010: 1022-1024.
27. O'Mahony C, Yesudian PD, Stanley M: Imiquimod use in the genital area and development of lichen sclerosus and lichen planus. Int J STD AIDS 2010; 21: 219-221.
28. Taylor CL, Maslen M, Kapembwa M: A case report of severe eczema following use of imiquimod 5% cream. Sex Trans Infect 2006; 82: 227-228. (Pubitemid 43901592)
29. Ruocco E, Baroni A, Rossiello L, Ruocco V: Imiquimod contact pemphigus: a comment. Eur J Obstet Gynecol Reprod Biol 2004; 115: 242-243.
30. Lo Schiavo A, Sangiuliano S, Puca RV, Brunetti G, Ruocco E, Cozzi R: Contact pemphigus: a side-effect of imiquimod therapy. Int J Dermatol 2008; 47: 765-767. (Pubitemid 352016098)
31. Perras C: Imiquimod 5% cream for actinic keratosis. Issues Emerg Health Technol 2004; 61: 1-4.
32. Lin R, Ladd DJ Jr, Powell DJ, Way BV: Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol 2004; 140: 889-890. (Pubitemid 38917868)
33. Mashiah J, Brenner S: Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment. Arch Dermatol 2005; 141: 908-909. (Pubitemid 41058081)
34. Bauza A, Del Pozo LJ, Saus C, Martin A: Pemphigus-like lesions induced by imiquimod. Clin Exp Dermatol 2009; 34:e60-62.
35. Sriprakash K, Godbolt A: Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma. Australas J Dermatol 2009; 50: 211-213.
36. Serrão VV, Páris FR, Feio AB: Genital vitiligo- like depigmentation following use of imiquimod 5% cream. Eur J Dermatol 2008; 18: 342-343.
37. Senel E, Seckin D: Imiquimod-induced vitiligo- like depigmentation. Indian J Dermatol Venereol Leprol 2007; 73: 423.
38. Mashiah J, Brenner S: Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol 2008; 33: 74-76. (Pubitemid 350308512)
39. Brown T, Zirvi M, Cotsarelis G, Gelfand JM: Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol 2005; 52: 715-640.
40. Gollnick H, Barona CG, Frank RG, et al: Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005; 15: 374-381. (Pubitemid 41337416)
41. Blyumin M: Vitiligo-like hypopigmentation with poliosis following treatment of superficial basal cell carcinoma with imiquimod. Dermatol Surg 2008; 34: 844-845. (Pubitemid 351792307)
42. Al-Dujaili Z, Hsu S: Imiquimod-induced vitiligo. Dermatol Online J 2007; 13: 10.
43. Stefanaki C, Nicolaidou E, Hadjivassiliou M, Antoniou C, Katsambas A: Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol 2006; 20: 755-756.
44. Vaccaro M, Barbuzza O, Guarneri B: Erosive pustular dermatosis of the scalp following treatment with topical imiquimod for actinic keratosis. Arch Dermatol 2009; 145: 1340-1341.
45. Conde J, Davis K, Ntuen E, Balmer N, Jones D, McMichael A: A case of imiquimod-induced alopecia. J Dermatolog Treat 2010; 21: 122-124.
46. Chakrabarty AK, Mraz S, Geisse JK, Anderson NJ: Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol 2005; 5: 35-37.
47. Zalaudek I, Petrillo G, Argenziano G: Aphthous ulcers and imiquimod. J Am Acad Dermatol 2005; 53: 360-361.
48. Campanelli A, Labbe J: Erosive cheilitis after facial application of imiquimod 5% cream. J Eur Acad Dermatol Venereol 2007; 21: 1429-1430. (Pubitemid 350020164)
49. Kaya TI, Tursen U, Ikizoglu G: Large genital ulcers in a patient with Behcet's disease associated with imiquimod cream treatment for external genital warts. Clin Exp Dermatol 2008; 33: 783-784.
50. Stephenson S, Nedorost S: Granuloma annulare: dramatically altered appearance after application of 5% imiquimod cream. Pediatr Dermatol 2008; 25: 138-139. (Pubitemid 351315482)
51. Yi BA, Nirenberg MJ, Goldstein SM, Berger TG: Chronic neuropathic pain associated with imiquimod: report of 2 cases. J Am Acad Dermatol 2005; 52: 57-58.
52. Campanelli A, Krischer J, Saurat JH: Topical application of imiquimod and associated fever in children. J Am Acad Dermatol 2005; 52:E1. (Pubitemid 40038926)
53. Benson E: Imiquimod: potential risk of an immunostimulant. Australas J Dermatol 2004; 45: 123-124. (Pubitemid 38607927)
54. Systemic reactions to imiquimod (Aldara). Med Lett Drugs Ther 2004; 46: 92.
55. Imiquimod: liver damage: topical use, systemic effects. Prescrire Int 2009; 18: 166.
56. Misery L: Treatment of genital Paget's skin disease with topical imiquimod: severe adverse events. J Dermatolog Treat 2007; 18: 191-192. (Pubitemid 46854826)
57. Wolfe CM, Tafuri N, Hatfield K: Exacerbation of myasthenia gravis during imiquimod treatment. J Drugs Dermatol 2007; 6: 745-746.
58. Agencia Española de Medicamentos y Productos Sanitarios: Ficha técnica imiquimod. 2009. fichasTecnicas.do?metodo=detalleForm (accessed July 15, 2009).
59. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D: Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512-516. (Pubitemid 26364720)
60. Shah M, Jenis EH, Mookerjee BK, Schriber JR, Baer MR, Herzig GP: Interferon α-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukaemia following high dose chemotherapy. Cancer 1998; 83: 1938-1946. (Pubitemid 28503725)